Loading... Please wait...

Point of Care Diagnostic Testing World Markets

Bookmark and Share
Price:
$3,850.00
Publication Date:
March 2015; Pages: 493
File Type:
Downloadable PDF


Description

 



Point of Care Report Sample


Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening. This TriMark Publications report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections--both in the U.S. and worldwide--including Europe, Asia and Latin America. It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

 

TABLE OF CONTENTS

1. Overview 20
1.1 About This Report 20
1.2 Scope of the Report 22
1.3 Objectives 22
1.4 Methodology 22
1.5 Executive Summary 24

2. Overview of Diagnostic Testing Point of Care Markets 28
2.1 Key Issues in the POC Diagnostic Testing Sector 31
2.1.1 Current Market Trends and Drivers 32
2.1.2 Effectiveness of POCT 33
2.1.3 New Growth Areas for POCT 34
2.1.4 Advantages of POCT in a Clinical Setting 34
2.1.5 Pricing and Reimbursement Issues 35
2.1.6 Key Customer Segments 35
2.2 Global Point of Care Marketplace 35
2.3 Shifts from Central Lab Testing to POCT 36
2.4 Geographical Distribution 36
2.5 Challenges of POCT 39
2.6 Key Issues for POCT 40
2.6.1 Locations of POCT 40
2.6.2 Milestones in Technology Development 42
2.6.3 Drive for Decentralization from Lab to Patient 42
2.6.4 Competitive Landscape for POCT 43
2.7 The Future of POCT 44

3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share 46
3.1 Global POCT Market 46
3.2 Global Market Revenues Analysis by Market Segment 47
3.2.1 Global POC Blood Glucose Monitoring Systems Market 47
3.2.2 Global POC Blood Gas and Electrolyte Analyzers Market 48
3.2.3 Global POC Rapid Coagulation Analyzers Market 48
3.2.4 Global POC Cardiac Markers Devices Market 49
3.2.5 Global POC Substance Abuse Testing Device Market 50
3.2.6 Global POC Infectious Disease Testing Device Market 50
3.2.7 Global POC Urine Strip Testing Market 51
3.2.8 Global POC Pregnancy Testing Device Market 51
3.2.9 Global POC Fecal Occult Device Market 52
3.2.10 Global POC Cholesterol Testing Market 52
3.3 Global Market Share Analysis 53
3.4 Global Market Size by Geographic Location 53
3.5 Global Market Size by Analyte Market Segment 54
3.6 Global POCT Testing by Location 55

4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share 56
4.1 U.S. Market Revenues Analysis by Market Segment 57
4.1.1 U.S. POC Blood Glucose Monitoring Systems Market 57
4.1.2 U.S. POC Blood Gas and Electrolyte Analyzers Market 57
4.1.3 U.S. POC Rapid Coagulation Analyzers Market 58
4.1.4 U.S. POC Cardiac Markers Devices Market 58
4.1.5 U.S. POC Substance Abuse Testing Device Market 60
4.1.6 U.S. POC Infectious Disease Testing Device Market 60
4.1.7 U.S. POC Urine Strip Testing Market 61
4.1.8 U.S. POC Pregnancy Testing Device Market 61
4.1.9 U.S. POC Fecal Occult Device Market 62
4.1.10 U.S. POC Cholesterol Testing Market 62
4.2 U.S. Market Share Analysis 63
4.3 U.S. Market Size by Analyte Market Segment 63

5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares 65
5.1 European Market Revenues Analysis 71
5.2 European Market Revenues Analysis by Geographic Region 72
5.2.1 French Revenues for POCT Systems 72
5.2.2 German Revenues for POCT Systems 73
5.2.3 Italian Revenues for POCT Systems 74
5.2.4 Spanish Revenues for POCT Systems 75
5.2.5 U.K. Revenues for POCT Systems 75
5.2.6 Benelux Revenues for POCT Systems 76
5.2.7 Scandinavian Revenues for POCT Systems 76
5.2.8 Rest of Europe Revenues for POCT Systems 77
5.3 European Market Revenues Analysis by Market Segment 76
5.3.1 European POC Blood Glucose Monitoring Systems Market 76
5.3.2 European POC Blood Gas and Electrolyte Analyzers Market 77
5.3.3 European POC Rapid Coagulation Analyzers Market 78
5.3.4 European POC Cardiac Marker Market 78
5.3.5 European POC Substance Abuse Testing Device Market 80
5.3.6 European POC Infectious Disease Testing Market 81
5.3.7 European POC Urine Strip Testing Market 82
5.3.8 European POC Pregnancy Testing Device Market 82
5.3.9 European POC Fecal Occult Blood Testing Market 83
5.3.10 European POC Cholesterol Testing Market 84
5.4 European Market Share Analysis 85

6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market
Share 86
6.1 Summary Analysis of Japanese, Chinese and Indian POCT Market Revenues 86
6.2 Summary of Asian (Japanese, Chinese and Indian) Market Revenues by Market Segment 87
6.2.1 Asian (Japanese, Chinese and Indian) POC Blood Glucose Monitoring Systems Market 87
6.2.2 Asian (Japanese, Chinese and Indian) POC Blood Gas and Electrolyte Analyzers Market 87
6.2.3 Asian (Japanese, Chinese and Indian) POC Rapid Coagulation Analyzers Market 88
6.2.4 Asian (Japanese, Chinese and Indian) POC Cardiac Markers Devices Market 88
6.2.5 Asian (Japanese, Chinese and Indian) POC Substance Abuse Testing Device Market 89
6.2.6 Asian (Japanese, Chinese and Indian) POC Infectious Disease Testing Device Market 89
6.2.7 Asian (Japanese, Chinese and Indian) POC Urine Strip Testing Market 90
6.2.8 Asian (Japanese, Chinese and Indian) POC Pregnancy Testing Device Market 90
6.2.9 Asian (Japanese, Chinese and Indian) POC Fecal Occult Device Market 91
6.2.10 Asian (Japanese, Chinese and Indian) POC Cholesterol Testing Market 91
6.3 Asian (Japanese, Chinese and Indian) Market Share Analysis 92
6.4 Summary Analysis of the Japanese POCT Market 92
6.5 Summary Analysis of the Indian POCT Market 94
6.6 Summary Analysis of the Chinese POCT Market 97

7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share 107
7.1 Summary Analysis of the ROW POCT Market Revenues 107
7.2 Summary of the ROW Market Revenues by Market Segment 108
7.2.1 ROW POC Blood Glucose Monitoring Systems Market 108
7.2.2 ROW POC Blood Gas and Electrolyte Analyzers Market 108
7.2.3 ROW POC Rapid Coagulation Analyzers Market 109
7.2.4 ROW POC Cardiac Markers Devices Market 109
7.2.5 ROW POC Substance Abuse Testing Device Market 110
7.2.6 ROW POC Infectious Disease Testing Device Market 110
7.2.7 ROW POC Urine Strip Testing Market 111
7.2.8 ROW POC Pregnancy Testing Device Market 111
7.2.9 ROW POC Fecal Occult Device Market 112
7.2.10 ROW POC Cholesterol Testing Market 112
7.3 ROW Market Share Analysis 113
7.4 Summary Analysis of the ROW POCT Market Revenues 113
7.4.1 Summary Analysis of the Argentinian POCT Market 113
7.4.2 Summary Analysis of the Australian POCT Market 114
7.4.3 Summary Analysis of the Brazilian POCT Market 114
7.4.4 Summary Analysis of the Canadian POCT Market 115
7.4.5 Summary Analysis of the Russian POCT Market 115
7.4.6 Summary Analysis of the Middle East POCT Market 116
7.4.7 Summary Analysis of the African POCT Market 117
7.4.8 Summary Analysis of the Asia (Other) POCT Market 118
7.4.9 Summary Analysis of the Latin America (Other) POCT Market 121

8. Review of the Market Segments, Reagents and Equipment 123
8.1 Blood Glucose Monitoring 123
8.1.1 Introduction to Blood Glucose Monitoring 123
8.1.2 Types of Blood Glucose Testing 124
8.1.2.1 Fasting Blood Sugar (FBS) or Fasting Plasma Glucose (FPG) 124
8.1.2.2 Two-Hour Postprandial Blood Sugar or Two-Hour PC 124
8.1.2.3 Random Blood Sugar (RBS) 124
8.1.2.4 Glucose Urine Test 124
8.1.2.5 Blood Glucose Test Strip 124
8.1.2.6 Glycosylated Hemoglobin (HbA1c) 125
8.1.2.7 Intravenous Glucose Tolerance Test (IVGTT) 125
8.1.2.8 Oral Glucose Tolerance Test (OGTT) 125
8.1.3 Segmentation of POC Blood Glucose Testing 125
8.1.3.1 Continuous Blood Glucose Monitoring (CBGM) 125
8.1.3.2 Self-Monitoring Blood Glucose (SMBG) Testing 126
8.1.3.3 Minimally-Invasive and Non-Invasive Blood Glucose Testing 126
8.1.3.4 Emerging Glucose Monitoring Technologies 127
8.1.3.5 Optical Transducer Technologies 127
8.1.3.6 Transdermal Sensor Technologies 129
8.1.3.7 Invasive Glucose Sensor Technologies 130
8.1.4 Review of Selected POC Blood Glucose Monitoring Systems 130
8.1.5 Review of Company Products 134
8.1.5.1 LifeScan 134
8.1.5.2 Roche Accu-Chek 137
8.1.5.3 Abbott Diabetes Care 139
8.1.5.4 HemoCue 140
8.1.5.5 Stanbio/GDS Technology 141
8.1.5.6 Abaxis, Inc. 141
8.1.5.7 Arkray (Japan) 142
8.1.5.8 Accurex (India) 142
8.1.5.9 Home Diagnostics, Inc. 142
8.1.5.10 Nova Biomedical 143
8.1.5.11 Bayer Diagnostics 143
8.1.5.11.1 Hemoglobin A1c Measurements 144
8.1.5.12 AgaMatrix 144
8.1.5.13 Arkray 144
8.1.5.14 EKF Diagnostics 145
8.1.5.15 ACON Laboratories, Inc. 145
8.1.5.16 Biosite (Now Part of Alere) 146
8.1.5.17 Siemens Healthcare Diagnostics 146
8.1.5.18 Infopia 146
8.1.5.19 Diasys 146
8.1.5.20 Quotient Dx 146
8.1.5.21 Cholestech (Acquired by Inverness Medical Innovations, now named Alere) 146
8.1.5.22 Bio-Rad 147
8.1.5.23 Axis-Shield 147
8.1.5.24 Abaxis, Inc. 147
8.1.6 Market Share for Glucose Testing 147
8.1.7 Competitive Analysis for the Glucose POCT Sector 148
8.1.8 Market Analysis 149
8.1.8.1 Market Drivers 149
8.1.8.2 Market Restraints 149
8.1.9 POC Glucose Testing Assay Market and Technology Trends 149
8.1.9.1 POC Glucose Testing Assay Market Trends 149
8.1.9.2 POC Glucose Testing Assay Technology Trends 150
8.1.9.3 POC Glucose Testing Assay Strategic Recommendations 150
8.2 Blood Gas and Electrolytes 151
8.2.1 Background to POC Blood Gas and Electrolyte Testing 151
8.2.1.1 Acid-Base Balance and the Lungs 153
8.2.1.2 Respiratory Acidosis 153
8.2.1.3 Respiratory Alkalosis 153
8.2.1.4 Metabolic (or Non-Respiratory) Acidosis 153
8.2.1.5 Metabolic (or Non-Respiratory) Alkalosis 153
8.2.1.6 Increasing Popularity of POC Blood Gas and Electrolyte Testing 154
8.2.2 Market Segmentation (Segmentation by Type of Blood Gas Monitoring Equipment) 154
8.2.2.1 Intermittent Blood Gas Monitoring Equipment 154
8.2.2.2 Continuous Blood Gas Monitoring Equipment 154
8.2.2.3 EABG Monitors 155
8.2.2.4 IABG Monitors 155
8.2.2.5 Portable Blood Gas Analyzers 155
8.2.2.6 Patient-Attached On-Demand Blood Gas Analyzers 156
8.2.3 Applications for POCT Blood Gas and Electrolyte Analyzers 156
8.2.4 Emerging Technologies 156
8.2.5 Whole-Blood Lactate 156
8.2.6 Creatinine 156
8.2.7 Electrolytes Point of Care Analysis: Comparison of POCT and Central Lab Results 157
8.2.8 Review of Selected Blood Gas and Electrolyte Analyzers 158
8.2.9 Review of Company Products 160
8.2.9.1 Roche Corporation 160
8.2.9.2 TechnoMedica 160
8.2.9.3 Siemens Healthcare Diagnostics 160
8.2.9.4 Instrumentation Laboratory 161
8.2.9.5 Nova Biomedical 162
8.2.9.6 Radiometer 162
8.2.9.7 Abbott Point of Care 163
8.2.9.8 Span Diagnostics 164
8.2.9.9 ITC AVOXimeter Systems for CO-Oximetry 164
8.2.9.10 ITC (Nexus Dx) 165
8.2.9.11 Alere 165
8.2.9.12 Abaxis, Inc. 166
8.2.9.13 Opti Medical 166
8.2.9.14 Arkray USA 166
8.2.10 Market Share for Blood Gas and Electrolyte Testing 166
8.2.11 Competitive Analysis for the Blood Gas and Electrolyte Point of Care Testing Sector 167
8.2.12 Market Analysis 169
8.2.12.1 Market Drivers 169
8.2.12.2 Market Restraints 169
8.2.13 POC Blood Gas and Electrolyte Testing Assay Market and Technology Trends 170
8.2.13.1 POC Blood Gas and Electrolyte Testing Assay Market Trends 170
8.2.13.2 POC Blood Gas and Electrolyte Testing Assay Technology Trends 170
8.2.13.3 POC Blood Gas and Electrolyte Testing Assay Strategic Recommendations 170
8.3 Rapid Coagulation Tests 171
8.3.1 Background to Rapid Coagulation Tests 172
8.3.2 Review of Selected POC Rapid Coagulation Analyzers 178
8.3.3 Review of Company Products 181
8.3.3.1 Roche Diagnostics Corp. 181
8.3.3.2 Abbott Laboratories 182
8.3.3.3 International Technidyne Corporation Nexus DX 183
8.3.3.4 Medtronic 185
8.3.3.5 Alere 185
8.3.3.6 Helena Laboratories Point of Care 186
8.3.3.7 Sienco, Inc. 187
8.3.3.8 Accriva Accumetrics (ITC Nexus Holding Company) 188
8.3.3.9 Alere 188
8.3.3.10 ITC 189
8.3.3.11 Instrumentation Laboratory’s GEM PCL Plus 189
8.3.3.12 Others 190
8.3.3.13 Self-Monitoring Products 190
8.3.3.14 Platelet Function and Antiplatelet Drug Assessment 190
8.3.4 Connectivity Issues 191
8.3.5 Cost Benefits 191
8.3.6 Quality Control Issues 192
8.3.7 Certification for POC Coagulation Devices 193
8.3.8 D-Dimer Testing 193
8.3.9 Market Analysis 193
8.3.9.1 Market Share for POCT Coagulation Testing 193
8.3.9.2 Competitive Analysis of Sector Companies 194
8.3.9.3 Market Drivers 194
8.3.9.4 Market Restraints 195
8.3.9.5 POC Coagulation Testing Assay Market Trends 196
8.3.9.6 POC Coagulation Testing Assay Technology Trends 196
8.3.9.7 POC Coagulation Testing Assay Strategic Recommendations 197
8.3.9.8 SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market 197
8.4 POC Rapid Cardiac Markers 198
8.4.1 Background to POC Rapid Cardiac Marker Testing 198
8.4.2 Cardiac Marker Tests 199
8.4.2.1 Creatine Kinase (CK) 199
8.4.2.2 Myoglobin 200
8.4.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 200
8.4.2.4 C-Reactive Protein (CRP) 200
8.4.2.5 Homocysteine 201
8.4.3 Emerging Markers 201
8.4.3.1 B-Type Natriuretic Peptide (BNP) 201
8.4.3.2 Myeloperoxidase (MPO) 201
8.4.3.3 Ischemia-Modified Albumin (IMA) 202
8.4.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 202
8.4.3.5 Fatty Acid-Binding Proteins (FABPs) 202
8.4.4 Review of Selected POC Cardiac Biomarker Analyzers 203
8.4.5 Review of Company Products 204
8.4.5.1 Alere Triage Cardiac Panel 204
8.4.5.2 Roche Diagnostics 205
8.4.5.3 Any Biotech 206
8.4.5.4 Response Biomedical Corporation 207
8.4.5.5 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation and Dade Behring) 208
8.4.5.6 Abbott Point of Care 208
8.4.5.7 LifeSign (Princeton BioMediTech Corp.) 208
8.4.5.8 Mitsubishi Kagaku Iatron 209
8.4.5.9 Alpha Scientific 209
8.4.5.10 bioMérieux 209
8.4.5.11 Nexus 209
8.4.5.12 Princeton BioMeditech 210
8.4.5.13 Randox Laboratories 210
8.4.5.14 Market Share for Cardiac Marker Testing 210
8.4.6 Market Analysis 211
8.4.6.1 Market Drivers 211
8.4.6.2 Market Restraints 212
8.4.7 POC Cardiac Marker Testing Assay Market and Technology Trends 213
8.4.7.1 POC Cardiac Marker Testing Assay Market Trends 213
8.4.7.2 POC Cardiac Marker Testing Assay Technology Trends 214
8.4.7.3 POC Cardiac Marker Testing Assay Strategic Recommendations 214
8.5 POC Substance Abuse Testing 215
8.5.1 Background to POC Substance Abuse Testing 215
8.5.2 Substance Abuse Test Types 222
8.5.2.1 Urine Substance/Drug Screening 222
8.5.2.2 Hair Tests for Substance Abuse and Screening 222
8.5.2.3 Blood Tests for Substance Abuse and Screening 223
8.5.2.4 Saliva Tests for Substance Abuse and Screening 223
8.5.2.5 Sweat Tests for Substance Abuse and Screening 223
8.5.3 Alcohol Abuse and Screening 223
8.5.4 Saliva Testing 224
8.5.5 Qualitative Analysis 224
8.5.5.1 Market Drivers 224
8.5.5.2 Market Restraints 225
8.5.6 Review of Selected POC Substance Abuse Analyzers 225
8.5.7 Review of Company Products 227
8.5.7.1 Alere 227
8.5.7.2 Abbott Diagnostics 228
8.5.7.3 BTNX, Inc. 228
8.5.7.4 BioScan Screening Systems, Inc. 229
8.5.7.5 American Bio Medica Corp. 229
8.5.7.6 Phamatech, Inc. 234
8.5.7.7 First Check Diagnostics Corp. (Alere, Inc.) 235
8.5.7.8 OraSure 235
8.5.7.9 Noble Medical, Inc. 235
8.5.7.10 Guangzhou Wondfo Biotech Co., Ltd. 236
8.5.7.11 Pathtech 236
8.5.7.12 Alfa Scientific Designs, Inc. 236
8.5.7.13 TCPI, Inc. 237
8.5.7.14 Biophor Diagnostics 237
8.5.7.15 Randox Laboratories 237
8.5.7.16 Branan Medical 238
8.5.7.17 Concateno 238
8.5.7.18 LifeSign 239
8.6 POC Pregnancy and Fertility Tests 239
8.6.1 Background to POC Pregnancy and Fertility Tests 239
8.6.2 Review of Selected POC Pregnancy Testing Devices 239
8.6.3 Review of Company Products 241
8.6.3.1 Quidel 241
8.6.3.2 Abbott Diagnostics 241
8.6.3.3 Alere 242
8.6.3.4 Worldwide Medical Corporation 242
8.6.3.5 Sekisui Diagnostics, LLC 242
8.6.3.6 Siemens Diagnostics 242
8.6.3.7 Orgenics (A subsidiary of Alere) 242
8.6.3.8 LifeSign 243
8.6.3.9 Stanbio 243
8.6.3.10 Market Analysis 243
8.6.3.10.1 Competitive Sector Analysis 243
8.7 Fecal Occult Blood 243
8.7.1 Background to POC Fecal Occult Blood Testing 244
8.7.2 Review of Selected POC Fecal Occult Testing Devices 246
8.7.3 Review of Company Products 248
8.7.3.1 Helena Laboratories 248
8.7.3.2 Biomerica 248
8.7.3.3 Beckman Coulter 248
8.7.3.4 Worldwide Medical 248
8.7.3.5 Aerscher Diagnostics 249
8.7.3.6 Enterix 249
8.7.3.7 Medix Biochemica 249
8.7.3.8 Orion Diagnostica 250
8.7.3.9 ACON Laboratories’ Mission FOB Reagent Strips 250
8.7.3.10 Alere’s Products 250
8.7.3.11 Immunostics’ Hema-Screen 250
8.7.3.12 Princeton BioMeditech’s BioSign iFOBTest 250
8.7.3.13 Quest Diagnostics’ InSure FIT 250
8.7.3.14 Quidel’s QuickVue iFOB 250
8.7.3.15 Exact Sciences’ Cologuard 250
8.7.3.16 Epigenomics 251
8.7.4 Market Share for Fecal Occult Blood Testing 251
8.7.4.1 Company Analysis for the Fecal Occult Blood POCT Sector 251
8.7.5 Market Analysis 251
8.7.5.1 Market Drivers 251
8.7.5.2 Market Restraints 252
8.7.5.3 POC Fecal Occult Blood Testing Assay Market and Technology Trends 252
8.7.5.3.1 POC Fecal Occult Blood Testing Assay Market Trends 252
8.7.5.3.2 Fecal Occult Blood Testing Assay Technology Trends 253
8.7.5.3.3 POC Fecal Occult Blood Testing Assay Strategic Recommendations 253
8.8 POC Infectious Disease Testing 254
8.8.1 Background to POC Infectious Disease Testing 254
8.8.2 Types of Diagnosis for Infectious Diseases 255
8.8.2.1 Microbial Culture 255
8.8.2.2 Microscopy 255
8.8.2.3 Biochemical Tests 255
8.8.2.4 Molecular Diagnostics 255
8.8.3 Diagnostic Platforms for Infectious Diseases 256
8.8.3.1 Centralized Laboratory Testing for Infectious Diseases 256
8.8.3.2 POC Testing for Infectious Diseases 256
8.8.4 Emerging Technologies 257
8.8.5 Qualitative Analysis 257
8.8.5.1 Market Drivers 257
8.8.5.2 Market Restraints 258
8.8.6 Review of Selected POC Infectious Disease Testing Devices 258
8.9 POC Urine Strip Testing 260
8.9.1 Background to POC Urine Strip Testing 260
8.9.2 Emerging Technologies 262
8.9.3 Review of Selected POC Urine Strip Testing Devices 262
8.10 POC Cholesterol Testing 264
8.10.1 POC Cholesterol Testing Market Size and Development 264
8.10.2 Background to POC Cholesterol Testing 264
8.10.3 POC Cholesterol Testing Devices 266
8.10.3.1 Review of Selected POC Cholesterol Testing Devices 266
8.10.4 Review of Company Products 267
8.10.4.1 Cholestech (Now Alere) 267
8.10.4.2 Actimed Laboratories 268
8.10.4.3 StatSite Meter 268
8.10.4.4 Polymer Technology Systems 269
8.10.4.5 Miraculins 269
8.10.4.6 Abaxis, Inc. 269
8.10.5 Product Comparison of Leading Suppliers 270
8.10.6 Launch Dates of Leading Products in Europe 272
8.11 Miscellaneous POC Tests 272
8.11.1 Triage C. difficile Panel 272
8.11.2 Ketoacids 272
8.11.3 Acetaminophen 273
8.11.4 Estriol 273
8.11.5 POC H. pylori Testing 274
8.11.6 Bacterial Contamination of Platelet Units 277
8.12 POC Vaginal Fluid pH and Vaginitis Testing 278
8.13 POC Cancer Testing 278
8.13.1 Prostate-Specific Antigen (PSA) 278
8.13.2 Bladder Cancer 279
8.13.3 Other Rapid Cancer Tests 283
8.14 Fetal Status (PROM) 283
8.15 Osteoporosis 284
8.16 Hemodynamic Monitoring 284
8.17 Heparin-Induced Thrombocytopenia 285
8.18 HIV 285
8.18.1 Whole-Blood, Serum or Plasma-Based HIV Tests 288
8.18.1.1 Bio-Rad Laboratories 288
8.18.1.2 Orgenics (Inverness, Now Alere) 289
8.18.1.3 StatSure Diagnostic Systems 289
8.18.1.4 Trinity Biotech 289
8.18.1.5 Savyon Diagnostics 289
8.18.1.6 MedPharm 290
8.18.1.7 American Bio Medica Corp. 290
8.18.1.8 Chembio Diagnostics 290
8.18.1.9 OraSure Technologies 291
8.18.1.10 Alere 292
8.18.1.11 Hema Diagnostics Systems 292
8.18.1.12 bioLytical Laboratories’ INSTI Kit 292
8.18.1.13 bioMérieux’s VIKIA HIV-1/2 Test 292
8.18.1.14 Chembio Diagnostics’ Dual-Path Platform Technology Products 293
8.18.1.15 Daktari Diagnostics’ Daktari CD4 293
8.18.1.16 EY Laboratories’ InstantCHEK 293
8.18.1.17 IND Diagnostic’s One-Step Anti-HIV (1+2) Test 293
8.18.1.18 IQuum’s Liat System 293
8.18.1.19 Lab21’s Biotec Tests 293
8.18.1.20 MedMira’s HIV Tests 293
8.18.1.21 YD Diagnostics’ AIDScan 294
8.18.2 Saliva-Based HIV Tests 294
8.18.2.1 OraSure Collection Device 295
8.18.2.2 SureStat 296
8.18.2.3 Calypte 296
8.18.3 Urine-Based HIV Tests 296
8.18.3.1 MedMira Laboratories, Inc. 296
8.18.3.2 Medical Services International, Inc. 297
8.18.3.3 Maxim Biomedical 297
8.18.3.4 Wampole Laboratories 298
8.19 Infectious Diseases 298
8.19.1 C. difficile 298
8.19.2 Giardia 299
8.19.3 Dengue Fever 299
8.19.4 Malaria Testing 299
8.19.5 Rapid Influenza Testing 301
8.19.6 Streptococcus Testing 305
8.19.7 Chlamydia 307
8.19.8 Mononucleosis 307
8.19.9 Rubella 308
8.19.10 Staphylococcus aureus and MRSA 308
8.19.11 Hepatitis 309
8.19.12 E. coli O157 313
8.19.13 Gonorrhea Testing 313
8.19.14 Smallpox 313
8.19.15 SARS 313
8.19.16 Rabies 313
8.19.17 Tuberculosis 313
8.19.18 Avian Flu 315
8.19.19 West Nile Virus 315
8.19.20 Herpes Simplex Virus Type-2 315
8.19.21 Legionella 316
8.19.22 RSV 316
8.19.23 Leptospirosis 318
8.19.24 Sexually-Transmitted Diseases 318
8.19.25 Infant Jaundice 319
8.19.26 Anthrax 320
8.19.27 Tropical Diseases 322
8.20 Homeland Defense (Plague and Tularemia) 322
8.21 BSE (Mad Cow Disease) 322
8.22 Tuberculosis 322
8.23 Typhoid 323
8.24 Avian Flu 323
8.25 Food Pathogens (Salmonella, Listeria, Campylobacter) 324
8.26 Ruptured Fetal Membranes 325
8.27 Alcohol 325
8.28 Microalbumin Testing 326
8.29 Prenatal, Labor and Delivery Testing 326
8.29.1 Alere Triage PLGF 326
8.29.2 Amnisure 326
8.29.3 Medix Biochemica 327
8.29.4 Sequenom, Verinata, Natera Prenatal Diagnostic Tests 327
8.30 Sperm Fertility 327
8.31 Surgical Coagulation and Hemostasis Management 327
8.32 Respiratory Tests 328
8.33 C-Reactive Protein 328

9. POCT: Growth Regulators 329
9.1 Moderators of Growth 329
9.2 Personnel Acceptance 329
9.3 Key People for POCT 330
9.4 Information Management Issues 330
9.4.1 Elements of Information Management for POCT: Information-Processing Capabilities 332
9.4.2 Data Mining 332
9.4.3 Middleware 333
9.4.4 Web Portals 333
9.4.5 POCT-1A Standard 333
9.5 Key Elements for POCT 334
9.6 POCT and Reimbursement 334
9.7 Effectiveness of Clinical Outcomes 336
9.8 Rapid Near-Patient Testing in Hospitals 337
9.9 Satellite Facilities 337
9.10 Regionalization of Laboratory Care 338
9.11 Requirements for POCT 339
9.12 Locations of POC for Patient Care 340
9.13 Benefits of POCT 341
9.14 Cost Elements of POCT 342
9.15 Necessary Functions in POCT 342
9.16 Turnaround Time (TAT) for POCT 342
9.17 Clinical Laboratory Improvement Amendments (CLIA) 343
9.18 Sexually-Transmitted Diseases in Underdeveloped Countries 345
9.19 Sources of Error in POC Testing 345

10. Business Trends in the POC Sector 348
10.1 Sector Consolidation 348
10.2 Diagnostic Testing Growth Trends 349
10.2.1 Opportunities for Healthcare Stakeholders 350
10.3 Acquisition, License Agreements, Internal Development and Partnerships 350
10.4 Product Testing Depth in POCT 354
10.5 Government Regulation 354
10.5.1 U.S. Regulation 354
10.5.1.1 Importing Medical Devices into the U.S. 356
10.5.1.2 Exporting Medical Devices from the U.S. 356
10.5.2 E.U. Regulation 357
10.5.3 Japanese Regulation 360
10.5.4 Korean Regulation 361
10.6 Post-Filing Regulations for POC Devices 361
10.7 Exporting Unapproved POCTs 362
10.8 Analyte-Specific Reagents (“Home-Brew” Tests) 362
10.9 Medical Device Registration 363
10.10 Product Labeling 363
10.11 Punitive FDA Actions 363
10.12 CLIA ‘88 and State Laboratory Laws 364
10.13 Impact of Regulations on the Industry 364
10.14 Minimizing Regulatory Barriers 365
10.15 Waived Testing 367

11. Technology Platform Innovations in POCT 369
11.1 Latest POCT Technological Platforms 369
11.1.1 Device Miniaturization and Microfluidic Technologies 369
11.1.2 Minimally-Invasive and Non-Invasive POCT Technologies 369
11.1.2.1 Via Medical 369
11.1.2.2 Echo Therapeutics 371
11.1.3 Advances in Wireless Technologies 371
11.1.4 Automation of POCT 371
11.1.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing
Technologies) 371
11.1.6 Advances in Informatics Technologies 374
11.1.7 Pharmacogenetic Testing 374
11.1.8 Multi-Assay Technologies in POCT 374
11.1.9 Molecular Diagnostic Technology in POCT for Infectious Disease 375
11.2 Developments in Key Technologies 375
11.2.1 Medical and Biological Sensors and Sensor Systems 375
11.2.2 Recent Biosensor Product Introductions and the Latest Innovative Developments 376
11.2.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers 376
11.2.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments 376
11.2.2.3 ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor 377
11.2.2.4 AgaMatrix Europe Limited Introduces New Jazz Blood Glucose Meter in the U.K. 377
11.2.2.5 STMicroelectronics to Manufacture the World’s Smallest Biosensors 377
11.2.2.6 Universal Biosensors Advances POC Molecular Diagnostic Opportunity 378
11.2.2.7 Clinitek Advantus—A Semi-Automated Urine Analyzer for POC Testing 378
11.2.2.8 NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-Based Seven-Test Chemistry
Profile 378
11.3 Sensor Systems for Diagnostic Applications 380
11.4 Nanogen (The ELITech Group) Third-Generation POC Analyzer 383
11.5 Philips Development of Magnotech Technology 383
11.6 Quidel Corporation MChip, AVR Chip and F Chip 383
11.7 Sanofi-Aventis 383
11.8 Siloam Biosciences Trova Open Source Point of Care System 384
11.9 Smart Phone Technology 384
11.9.1 Aquila Diagnostic Systems, Inc. 385
11.9.2 AgaMatrix 385
11.9.3 Quick HIV and Syphilis Screening 386
11.10 Sirigen HSF Technology 386
11.11 QuantuMDx Handheld, Portable Low Cost Rapid Devices 387

12. Data Management and Connectivity 388
12.1 Wireless LANs 388
12.2 Connectivity Platforms 390
12.2.1 Data Management System 391
12.2.2 RALS-Plus, RALS-Web3 and RALS-Freedom 393
12.2.2.1 International Technidyne Corporation HEMOCHRON Signature Elite 394
12.2.2.2 Siemens Diagnostics Rapidpoint Coag 394
12.2.2.3 Radiometer 394
12.2.2.4 HemoCue’s DM Hemoglobin 395
12.2.2.5 Roche Diagnostics 395
12.2.2.6 Accriva 395
12.2.3 BD.id 395
12.2.4 Medical Implant Communications Service (MICS) 395
12.2.5 Conworx Technology 396
12.2.6 Lab Data Systems 396
12.2.7 Medasys 396
12.2.8 NoemaLife 396
12.2.9 Telcare 397
12.3 Advantages of POCT Connectivity 397
12.3.1 Cost-Benefit Analysis of POCT and IT Connectivity 397
12.3.2 Hospital Network Issues 398
12.4 POCT Analyzer Connectivity Software Solutions 398
12.5 POCT2-P 400

13. Corporate Profiles 401
13.1 Abaxis, Inc. 401
13.2 Abbott Laboratories 404
13.3 AccuBioTech Co., Ltd. 406
13.4 Accriva Diagnostics 406
13.5 AccuTech, LLC 407
13.6 ACON Laboratories, Inc. 407
13.7 Acrongenomics 408
13.8 AgaMatrix 408
13.9 Aerscher Diagnostics, LLC 409
13.10 Akers Biosciences, Inc. 409
13.11 Alere 411
13.12 Alfa Scientific Designs, Inc. 415
13.13 American Bio Medica Corporation 415
13.14 Any Biotech Oyo Ltd. 416
13.15 Ark Therapeutics Group Plc 417
13.16 Arkray, Inc. 417
13.17 Atlas Genetics Ltd. 418
13.18 Atonomics A/S 418
13.19 Audit Diagnostics 418
13.20 Augurix Diagnostics Ltd. 419
13.21 Axis-Shield Plc (Alere) 419
13.22 Axxin 420
13.23 Bayer Corp. 420
13.24 Beckman Coulter (Danaher Corporation) 421
13.25 BioLytical Laboratories 424
13.26 Biomerica, Inc. 425
13.27 bioMérieux 426
13.28 BiOracle 426
13.29 Bio-Rad Laboratories, Inc. 426
13.30 BioScan Screening Systems, Inc. 428
13.31 BioSite 428
13.32 Calmark Sweden AB 428
13.33 Calypte Biomedical Corporation 428
13.34 Chembio Diagnostic, Inc. 429
13.35 Chempaq A/S 429
13.36 Cholestech 429
13.37 Claros Diagnostics (OPKO Healthcare) 430
13.38 CompuCyte Corporation (Thorlabs) 430
13.39 Concateno Plc 430
13.40 Dexcom 430
13.41 Diagnostics for All 431
13.42 Enigma Diagnostics Ltd. 432
13.43 EY Laboratoires, Inc. 432
13.44 Eurotrol 433
13.45 Exalenz Bioscience 433
13.46 GenBio 434
13.47 Genzyme Diagnostics (Acquired by Sekisui Chemical Co., Ltd.) 434
13.48 Guided Therapeutics, Inc. (SpectRx, Inc.) 434
13.49 Helena Laboratories 435
13.50 Hema Diagnostic Systems, LLC 435
13.51 HemoCue AB 436
13.52 HemoSense 436
13.53 Home Diagnostics (Nipro Diagnostics) 436
13.54 IND Diagnostic 436
13.55 Instrumentation Laboratory (IL)/Werfen Group 436
13.56 Jant Pharmacal Corporation 437
13.57 Johnson & Johnson 437
13.58 Lein Applied Diagnostics 438
13.59 LifeAssays AB 438
13.60 LifeSign, LLC 439
13.61 Medica Corporation 439
13.64 Mediwatch 439
13.65 Medix Biochemica 439
13.66 MedMira Laboratories 440
13.67 MELA Sciences (Formerly Electro-Optical Sciences) 441
13.68 A. Menarini Diagnostics 442
13.69 Meretek Diagnostics Group 442
13.70 Meridian Bioscience 442
13.71 Micronics 443
13.72 Minimed, Inc. 444
13.73 Mitsubishi Chemical Holdings USA, Inc. 444
13.74 Mitsubishi Kagaku Iatron 445
13.75 Nanogen (ELITech Group) 445
13.76 New Horizons Diagnostics 446
13.77 Nova Biomedical 446
13.78 OraSure Technologies, Inc. 448
13.79 Orion Diagnostica 450
13.80 Polymedco, Inc. 450
13.81 Polymer Technology Systems, Inc. 451
13.82 Prima Biomedical Company 452
13.83 QBC Diagnostics 452
13.84 Qualigen 452
13.85 Quest Diagnostics, Inc. 452
13.86 Quidel Corporation 453
13.87 Radiometer Medical 457
13.88 Response Biomedical Corp. 461
13.89 Roche Diagnostics 462
13.90 Savyon Diagnostics 464
13.91 Seegene 465
13.92 Sekisui Diagnostics, LLC 465
13.93 Shanghai Ruicare Medical Co., Ltd. 466
13.94 Shenzhen Fitconn Technology Co., Ltd. 466
13.95 Shionogi & Co., Ltd. 466
13.96 Siemens AG 466
13.97 Siloam Biosciences, Inc. 468
13.98 Spectral Diagnostics, Inc. 468
13.99 StatSure Diagnostic Systems, Inc. 469
13.100 Step Detect Associates, LLC 469
13.101 Strategic Diagnostics, Inc. 470
13.102 Techne Corporation 470
13.103 Telcare 471
13.104 Trinity Biotech Plc 472
13.105 Väsamed, Inc. 475

14. POCT Sector Trends and Forecasts 476
14.1 Home Care Analysis as Part of Near-Patient Testing 476
14.2 Non-Traditional Collection for POCT 476
14.3 New Systems for Critical Care and Near-Patient Testing 476
14.4 Utility of Near-Patient Testing in Critical-Care Settings 477
14.5 Physician’s Office Market 477
14.6 Information Management Advances 478
14.7 Test-Ordering Patterns and Demand for POCT 478
14.8 Demand for Emergency Department Services 478
14.9 Move Away from the Central Laboratory 479
14.10 Healthcare Cost Controls 480
14.11 Mergers and Acquisitions in POCT 481
14.12 Competition for Services 481
14.13 Drivers of POCT 482
14.14 Confluence of New Technology 482
14.15 Difficulties of Design for POC Products 482
14.16 European Hospital Structure 482
14.17 The Biggest New Opportunities in POCT 483

15. New Entrants to the Point of Care Market 484
15.1 Alliance International Co., Ltd. 484
15.2 Alverix, Inc. 484
15.3 Analyticon Biotechnologies AG 484
15.4 Ativa Medical Corporation 484
15.5 Aquila Diagnostic Systems, Inc. 485
15.6 ArcDia International Oyo Ltd. 485
15.7 Artron Laboratories, Inc. 486
15.8 Atlas Link Biotech Co., Ltd. 486
15.9 Audit Diagnostics 486
15.10 Autobio Diagnostics Co., Ltd. 487
15.11 Biocartis SA 487
15.12 BioFire Diagnostics, Inc. 487
15.13 BioHelix Corporation 488
15.14 BioMedomics 488
15.15 Biosensia Ltd. 488
15.16 Curetis AG 489
15.17 DxNA, LLC 489
15.18 Echo Therapeutics, Inc. 489
15.19 Gentag, Inc. 490
15.20 Great Basin Corporation 490
15.21 Immunexpress Group 490
15.22 Innovative Biosensors, Inc. 490
15.23 Integrated Diagnostics 490
15.24 Integrity Applications 491
15.25 MBio Diagnostics, Inc. 491
15.26 Menssana Research, Inc. 492
15.27 Metaara Medical Technologies, Inc. 492
15.28 QuantuMDx Group 492
15.29 Venaxis, Inc. 492
15.30 Vivacta Limited 492
15.31 Wave 80 Biosciences 493
15.32 Veredus Laboratories Pte Ltd. 493
15.33 Via Medical Corporation 494
15.34 Vital Diagnostics, Inc. 494


INDEX OF FIGURES

Figure 2.1: Worldwide Distribution of IVD Testing, 2013 37
Figure 2.2: Top 13 Country IVD Testing Markets, 2013 38
Figure 2.3: Market Share for IVD Testing by Company, 2013 39
Figure 3.1: Total Global POCT Market, 2008-2018 47
Figure 3.2: Worldwide Distribution of POCT, 2014 54
Figure 3.3: Summary of Global POCT Markets by Market Segment, 2014 55
Figure 4.1: U.S. Revenues for POCT Market, 2008-2018 56
Figure 4.2: Summary of U.S. POCT Markets by Market Segment, 2014 64
Figure 5.1: European Revenues for POCT Market, 2008-2018 72
Figure 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018 86
Figure 6.2: Japanese Revenues for POCT Market, 2008-2018 94
Figure 6.3: Indian Revenues for POCT Market, 2008-2018 97
Figure 6.4: Chinese Revenues for POCT Market, 2008-2018 100
Figure 7.1: Summary Analysis of ROW POCT Market, 2008-2018 107
Figure 7.2: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018 116
Figure 7.3: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018 117
Figure 7.4: Summary Analysis of African Revenues for POCT Products Market, 2008-2018 118
Figure 7.5: Summary Analysis of Latin America (Other) Revenues for POCT Products Market,
2008-2018 122
Figure 8.1: Global Share of Glucose Testing Market by Company, 2014 147
Figure 8.2: Global POCT Share of Blood Gas and Electrolyte Testing Market, 2014 166
Figure 8.3: Global POCT Share of Coagulation Testing Market, 2014 193
Figure 8.4: Global POCT Share of Cardiac Marker Testing Market, 2014 210
Figure 8.5: Global POCT Share of HIV Testing Market, 2014 288
Figure 8.6: Performance Metrics of ROM Diagnostic Methods 326
Figure 9.1: Annual Rate of Emergency Room Visits by Primary Expected Source of Payment 336
Figure 9.2: CLIA Laboratories by Certificate Types 343
Figure 10.1: Conformity Assessment Route, Annexes and Quality System Standards by IVD Device
Category 358
Figure 12.1: The RALS Data Management System Connects to Most of the Major Instruments Used in Point of
Care 392
Figure 12.2: AegisPOC Point of Care and Critical Care Connectivity and Information Management
System 399


INDEX OF TABLES

Table 2.1: Summary of Global POCT Markets by Major Market Sub-Segment, 2014 and 2018 28
Table 2.2: Summary of U.S. POCT Markets by Major Market Sub-Segment, 2014 and 2018 28
Table 2.3: Summary of European POCT Markets by Major Market Sub-Segment, 2014 and 2018 29
Table 2.4: Summary of Asian POCT Markets by Major Market Sub-Segment, 2014 and 2018 29
Table 2.5: Summary of ROW POCT Markets by Major Market Sub-Segment, 2014 and 2018 30
Table 2.6: Worldwide Distribution of IVD Testing, 2013 37
Table 2.7: Top 13 Country IVD Testing Markets, 2013 38
Table 2.8: Company Market Share for IVD Testing Markets, 2013 39
Table 2.9: Competitive Landscape for POC Diagnostic Testing 43
Table 3.1: Total Global POCT Market, 2008-2018 46
Table 3.2: Global Revenues for POC Blood Glucose Monitoring Systems, 2008-2018 47
Table 3.3: Global Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018 48
Table 3.4: Global Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018 49
Table 3.5: Global Revenues for POC Cardiac Marker Devices, 2008-2018 49
Table 3.6: Global Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018 50
Table 3.7: Global Revenues for POC Infectious Disease Testing Devices Market, 2008-2018 50
Table 3.8: Global Revenues for POC Urine Strip Testing Products Market, 2008-2018 51
Table 3.9: Global Revenues for POC Pregnancy Testing Devices Market, 2008-2018 51
Table 3.10: Global Revenues for POC Fecal Occult Testing Devices Market, 2008-2018 52
Table 3.11: Global Revenues for POC Cholesterol Testing Products Market, 2008-2018 52
Table 3.12: Global POCT Market Share Analysis, 2014 53
Table 3.13: Worldwide POCT Market Size by Geographic Location, 2008-2018 53
Table 3.14: Worldwide Distribution of POCT, 2014 54
Table 3.15: Summary of Global POCT Markets by Market Segment, 2014 54
Table 3.16: Worldwide POCT by Performance Location, 2014 55
Table 4.1: U.S. Revenues for POCT Market, 2008-2018 56
Table 4.2: U.S Revenues for POC Blood Glucose Monitoring Systems, 2008-2018 57
Table 4.3: U.S. Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018 58
Table 4.4: U.S. Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018 58
Table 4.5: U.S. Revenues for POC Cardiac Marker Devices, 2008-2018 59
Table 4.6: Market Share of U.S. POCT Cardiac Marker Market, 2013 59
Table 4.7: U.S. Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018 60
Table 4.8: U.S. Revenues for POC Infectious Disease Testing Devices Market, 2008-2018 60
Table 4.9: U.S. Revenues for POC Urine Strip Testing Products Market, 2008-2018 61
Table 4.10: U.S. Revenues for POC Pregnancy Testing Devices Market, 2008-2018 61
Table 4.11: U.S. Revenues for POC Fecal Occult Testing Devices Market, 2008-2018 62
Table 4.12: U.S. Revenues for POC Cholesterol Testing Products Market, 2008-2018 62
Table 4.13: U.S. POCT Market Share Analysis, 2013 63
Table 4.14: Summary of U.S. POCT Markets by Market Segment, 2014 63
Table 5.1: Models of Public-Private Partnership in Hospital Provision 68
Table 5.2: European Revenues for POCT Market, 2008-2018 71
Table 5.3: French Revenues for POCT Systems, 2008-2018 72
Table 5.4: German Revenues for POCT Systems, 2008-2018 73
Table 5.5: Italian Revenues for POCT Systems, 2008-2018 73
Table 5.6: Spanish Revenues for POCT Systems, 2008-2018 74
Table 5.7: U.K. Revenues for POCT Systems, 2008-2018 74
Table 5.8: Benelux Revenues for POCT Systems, 2008-2018 75
Table 5.9: Scandinavian Revenues for POCT Systems, 2008-2018 75
Table 5.10: Rest-of-Europe Revenues for POCT Systems, 2008-2018 76
Table 5.11: European Revenues for POC Blood Glucose Monitoring Systems, 2008-2018 77
Table 5.12: European Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018 77
Table 5.13: European Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018 78
Table 5.14: European Revenues for POC Cardiac Marker Devices, 2008-2018 80
Table 5.15: European Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018 81
Table 5.16: European Revenues for POC Infectious Disease Testing Devices Market, 2008-2018 81
Table 5.17: European Revenues for POC Urine Strip Testing Products Market, 2008-2018 82
Table 5.18: European Revenues for POC Pregnancy Testing Devices Market, 2008-2018 83
Table 5.19: European Revenues for POC Fecal Occult Testing Devices Market, 2008-2018 83
Table 5.20: European Revenues for POC Cholesterol Testing Products Market, 2008-2018 84
Table 5.21: European Market Share Analysis, 2013 85
Table 6.1: Summary Analysis of Japanese, Chinese and Indian POCT Market, 2008-2018 86
Table 6.2: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Glucose Monitoring Systems, 2008-2018 87
Table 6.3: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Blood Gas and Electrolyte Analyzers, 2008-2018 87
Table 6.4: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Rapid Coagulation Analyzer Systems, 2008-2018 88
Table 6.5: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cardiac Marker Devices, 2008-2018 88
Table 6.6: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Substance/Drug Abuse Testing Device Market, 2008-2018 89
Table 6.7: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Infectious Disease Testing Devices Market, 2008-2018 89
Table 6.8: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Urine Strip Testing Products Market, 2008-2018 90
Table 6.9: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Pregnancy Testing Devices Market, 2008-2018 90
Table 6.10: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Fecal Occult Testing Devices Market, 2008-2018 91
Table 6.11: Summary Analysis of Japanese, Chinese and Indian Revenues for POC Cholesterol Testing Products Market, 2008-2018 91
Table 6.12: Summary Analysis of Japanese, Chinese and Indian Market Shares, 2013 92
Table 6.13: Japanese Population and Aging Demographics Forecast, 2000-2050 93
Table 6.14: Japanese Revenues for POCT Market, 2008-2018 93
Table 6.15: Indian Revenues for POCT Market, 2008-2018 97
Table 6.16: Chinese Revenues for POCT Market, 2008-2018 99
Table 7.1: Summary Analysis of ROW POCT Market, 2008-2018 107
Table 7.2: Summary Analysis of ROW Revenues for POC Blood Glucose Monitoring Systems,
2008-2018 108
Table 7.3: Summary Analysis of ROW Revenues for POC Blood Gas and Electrolyte Analyzers,
2008-2018 108
Table 7.4: Summary Analysis of ROW Revenues for POC Rapid Coagulation Analyzer Systems,
2008-2018 109
Table 7.5: Summary Analysis of ROW Revenues for POC Cardiac Marker Devices, 2008-2018 109
Table 7.6: Summary Analysis of ROW Revenues for POC Substance/Drug Abuse Testing Device Market,
2008-2018 110
Table 7.7: Summary Analysis of ROW Revenues for POC Infectious Disease Testing Devices Market,
2008-2018 110
Table 7.8: Summary Analysis of ROW Revenues for POC Urine Strip Testing Products Market,
2008-2018 111
Table 7.9: Summary Analysis of ROW Revenues for POC Pregnancy Testing Devices Market,
2008-2018 111
Table 7.10: Summary Analysis of ROW Revenues for POC Fecal Occult Testing Devices Market,
2008-2018 112
Table 7.11: Summary Analysis of ROW Revenues for POC Cholesterol Testing Products Market,
2008-2018 112
Table 7.12: Summary Analysis of ROW Market Shares, 2013 113
Table 7.13: Summary Analysis of Argentinian Revenues for POCT Products Market, 2008-2018 113
Table 7.14: Summary Analysis of Australian Revenues for POCT Products Market, 2008-2018 114
Table 7.15: Summary Analysis of Brazilian Revenues for POCT Products Market, 2008-2018 114
Table 7.16: Summary Analysis of Canadian Revenues for POCT Products Market, 2008-2018 115
Table 7.17: Summary Analysis of Russian Revenues for POCT Products Market, 2008-2018 115
Table 7.18: Summary Analysis of Middle East Revenues for POCT Products Market, 2008-2018 116
Table 7.19: Summary Analysis of African Revenues for POCT Products Market, 2008-2018 117
Table 7.20: Summary Analysis of Asia (Other) Revenues for POCT Products Market, 2008-2018 118
Table 7.21: Summary Analysis of Latin America (Other) Revenues for POCT Products Market,
2008-2018 121
Table 8.1: Summary of Emerging Glucose Sensor Technologies, 2014 128
Table 8.2: Selected POC Blood Glucose Monitoring Systems, 2014 131
Table 8.3: Roche Diagnostics Glucose Testing Products 139
Table 8.4: Global Share of Glucose Testing Market by Company, 2014 148
Table 8.5: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Glucose POC Market 151
Table 8.6: Distribution of Blood Gas Testing in Hospitals, 1990 and 2012 152
Table 8.7: Selected POC Blood Gas and Electrolyte Analyzers, 2014 159
Table 8.8: Market Share of Blood Gas and Electrolyte POCT Diagnostic Testing Companies Worldwide,
2014 167
Table 8.9: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Blood Gas and Electrolyte POC Market 171
Table 8:10: Hospital Locations of Point of Care Coagulation Testing 173
Table 8.11: Selected POC Rapid Coagulation Analyzers, 2014 179
Table 8.12: Actalyke XL 187
Table 8.13: Actalyke Mini 187
Table 8.14: Market Share for Coagulation POCT Diagnostic Testing Companies, 2014 194
Table 8:15: Drivers for Point of Care Coagulation Testing 196
Table 8:16: Barriers for Point of Care Coagulation Testing 196
Table 8.17: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Coagulation POC Market 197
Table 8.18: Selected POC Cardiac Biomarkers, 2014 203
Table 8.19: Market Share of Cardiac Marker POCT Diagnostic Testing Companies Worldwide, 2014 211
Table 8.20: POC Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact 212
Table 8.21: POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact 213
Table 8.22: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Cardiac Marker POC Market 214
Table 8.23: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department 221
Table 8.24: Stat Urine Testing Drug Recommendations 221
Table 8.25: Selected POC Substance/Drug Abuse Testing Devices, 2014 226
Table 8.26: Selected POC Pregnancy Testing Devices, 2012 240
Table 8.27: Selected POC Fecal Occult Testing Devices, 2014 246
Table 8.28: ColoCARE Fecal Occult Blood Test 248
Table 8.29: SWOT Analysis: Summary of Strengths, Weaknesses, Opportunities and Threats in the Fecal Occult Blood POC Market 253
Table 8.30: Selected POC Infectious Disease Testing Devices, 2014 258
Table 8.31: Selected POC Urine Strip Testing, 2014 263
Table 8.32: Selected POC Cholesterol Testing Devices, 2014 266
Table 8.33: Competitive Factors Related to HIV Tests 287
Table 8.34: Global POCT Share of HIV Testing Market, 2014 288
Table 8.35: Influenza Diagnostic Rapid Tests 302
Table 8.36: Type of Hepatitis Test: Lateral Flow 311
Table 8.37: Type of Hepatitis Test: Flow-Through 312
Table 8.38: Type of Hepatitis Test: Agglutination 312
Table 8.39: Type of Hepatitis Test: Immunoblot 312
Table 8.40: AmniSure 325
Table 9.1: Access Points 331
Table 9.2: Desktop Adapters—Four Computers 331
Table 9.3: Desktop Adapters—One Computer 331
Table 9.4: PCMCIA Adapters 331
Table 9.5: POCT1-Compliant Connectivity POC Instruments 334
Table 9.6: POCT Clinical Outcomes in Diabetic Ketoacidosis 337
Table 9.7: POCT Clinical Outcomes in Arterial Blood-Gas Measurements 337
Table 9.8: POCT in Three Hospitals—Cost Analysis with Labor Included 340
Table 9.9: POCT versus Central Lab—Cost Analysis for Glucose Testing 340
Table 9.10: CLIA Laboratories by Type of Facility 341
Table 9.11: Financial Comparison for Moderate and Waived CLIA Labs 344
Table 9.12: Top Ten CMS Survey Deficiencies for CLIA Laboratories 347
Table 10.1: Key Changes in IVD Business Structure 353
Table 11.1: Common Genotype Techniques 372
Table 12.1: Applications for Wireless LAN Technology 388
Table 12.2: Customized Reports Must Support CAP and JCAHO Requirements 391
Table 12.3: Applications of RALS Connectivity with POCT Devices 393
Table 13.1: Abaxis Blood Analysis Diagnostic Tests 402
Table 13.2: Reagent Discs Offered with the Piccolo Chemistry Analyzers 403
Table 13.3: Products Marketed by Abbott in the Diagnostic Market 405
Table 13.4: Alere, Inc.—Net Sales by Geographic Region, 2009-2013 414
Table 13.5: BioRad Laboratories, Inc.—Sales by Business Sector, 2008-2013 427
Table 13.6: BioRad Laboratories, Inc.—Sales by Geography, 2010-2012 427
Table 13.7: Johnson & Johnson Financial Figures—Net Sales by Major Medical and Diagnostics Businesses,
2010-2013 438
Table 13.8: Quidel Product Distribution and Sales, 2012 and 2013 457
Table 13.9: Danaher Corporation Financial Figures—Net Sales by Business Sector, 2009-2013 458
Table 13.10: Danaher Corporation Financial Figures—Net Sales by Geographic Region, 2010-2013 458
Table 13.11: Roche Group Financial Figures—Net Sales by Business Sector, 2008-2013 463
Table 13.12: Roche Group Diagnostics Division—Net Sales by Geographic Region, 2012 and 2013 463
Table 13.13: Roche Group Financial Figures—Net Sales by Diagnostics Sub-Division, 2008-2013 463
Table 14.1: Improvements in Achieving ED Operational Efficiency Using POCT 477
Table 14.2: Test Menu and TAT for ED 478
Table 14.3: Top Reasons Why POC Cardiac Marker Testing is Implemented in the ED 478
Table 14.4: Key Areas and Metrics that Hospitals Measure to Assess Efficiency of ED 479
Table 14.5: Estimates of Patient Costs by DRG 481

Find Similar Products by Category